Sold as Detectnet. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Copper Cu-64 Dotatate (sold as Detectnet), first approved Sep 3, 2020, with 0 new uses approved and 0 published complete response letters.
| Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging of Neuroblastoma and Pheochromocytoma/ParagangliomaNeuroblastoma, Pheochromocytoma · Nanjing First Hospital, Nanjing Medical University | — | Recruiting | Sep 26, 2025 |
| Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.Digestive System Neuroendocrine Tumor, Unresectable Digestive System Neuroendocrine Neoplasm · Emory University | Phase 1 | Recruiting | Sep 2, 2025 |
| Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine TumorsGrade1-2 Advanced Midgut Neuroendocrine Tumors (NETs) · Grupo Espanol de Tumores Neuroendocrinos | Phase 3 | Recruiting | Mar 17, 2025 |
| 64Cu-DOTATATE-PET for Lyme NeuroborreliosisBorrelia Burgdorferi Neuroborreliosis · Copenhagen University Hospital, Rigshospitalet | Not applicable | Recruiting | Apr 30, 2024 |
| NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.Metastatic Neuroendocrine Prostate Cancer · Novartis Pharmaceuticals | Phase 1 | Active, not recruiting | Apr 23, 2024 |
| Macrophage PET/CT Imaging Using 64Cu-DOTATATE for the Diagnosis of Cardiac SarcoidosisCardiac Sarcoidosis · Copenhagen University Hospital, Rigshospitalet | — | Recruiting | Nov 14, 2023 |
| Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine TumorsDigestive System Neuroendocrine Tumor G1, Digestive System Neuroendocrine Tumor G2 · Vanderbilt-Ingram Cancer Center | Phase 4 | Recruiting | Aug 30, 2023 |
| Spanish Series of Patients Treated With the Radionuclide Lutetium177Neuroendocrine Tumors, Intestinal Neoplasms · Sociedad Española de Medicina Nuclear e Imagen Molecular | — | Recruiting | Jul 2, 2021 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
